These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 24965756

  • 21. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
    Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH, Dou QP.
    Cancer Res; 2007 May 01; 67(9):4303-10. PubMed ID: 17483343
    [Abstract] [Full Text] [Related]

  • 22. Chitosan nanoparticles enhance the plasma exposure of (-)-epigallocatechin gallate in mice through an enhancement in intestinal stability.
    Dube A, Nicolazzo JA, Larson I.
    Eur J Pharm Sci; 2011 Oct 09; 44(3):422-6. PubMed ID: 21925598
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Nanochemoprevention by encapsulation of (-)-epigallocatechin-3-gallate with bioactive peptides/chitosan nanoparticles for enhancement of its bioavailability.
    Hu B, Ting Y, Yang X, Tang W, Zeng X, Huang Q.
    Chem Commun (Camb); 2012 Feb 28; 48(18):2421-3. PubMed ID: 22266839
    [Abstract] [Full Text] [Related]

  • 26. Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro.
    Li GX, Chen YK, Hou Z, Xiao H, Jin H, Lu G, Lee MJ, Liu B, Guan F, Yang Z, Yu A, Yang CS.
    Carcinogenesis; 2010 May 28; 31(5):902-10. PubMed ID: 20159951
    [Abstract] [Full Text] [Related]

  • 27. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25.
    Zan L, Chen Q, Zhang L, Li X.
    Bioengineered; 2019 Dec 28; 10(1):374-382. PubMed ID: 31431131
    [Abstract] [Full Text] [Related]

  • 28. Folate decorated epigallocatechin-3-gallate (EGCG) loaded PLGA nanoparticles; in-vitro and in-vivo targeting efficacy against MDA-MB-231 tumor xenograft.
    Kazi J, Sen R, Ganguly S, Jha T, Ganguly S, Chatterjee Debnath M.
    Int J Pharm; 2020 Jul 30; 585():119449. PubMed ID: 32464231
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration.
    Lemarié F, Chang CW, Blatchford DR, Amor R, Norris G, Tetley L, McConnell G, Dufès C.
    Nanomedicine (Lond); 2013 Feb 30; 8(2):181-92. PubMed ID: 22891867
    [Abstract] [Full Text] [Related]

  • 31. Antibacterial Activity of Epigallocatechin-3-gallate (EGCG) Loaded Lipid-chitosan Hybrid Nanoparticle against Planktonic Microorganisms.
    Moreno APD, Marcato PD, Silva LB, Salvador SLS, Arco MCGD, Moraes JCB, Silva RSD, Rossi A.
    J Oleo Sci; 2024 Feb 30; 73(5):709-716. PubMed ID: 38692893
    [Abstract] [Full Text] [Related]

  • 32. Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo.
    Liu L, Hou L, Gu S, Zuo X, Meng D, Luo M, Zhang X, Huang S, Zhao X.
    Oncol Rep; 2015 Jan 30; 33(1):297-303. PubMed ID: 25333353
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Nanochemoprevention with therapeutic benefits: An updated review focused on epigallocatechin gallate delivery.
    Yang QQ, Wei XL, Fang YP, Gan RY, Wang M, Ge YY, Zhang D, Cheng LZ, Corke H.
    Crit Rev Food Sci Nutr; 2020 Jan 30; 60(8):1243-1264. PubMed ID: 30799648
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Antitumor/anti-angiogenesis efficacy of epigallocatechin gallate nanoformulated with antioxidant in melanoma.
    Sudha T, Salaheldin TA, Darwish NH, Mousa SA.
    Nanomedicine (Lond); 2022 Jun 30; 17(15):1039-1053. PubMed ID: 36102916
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models.
    Wei R, Mao L, Xu P, Zheng X, Hackman RM, Mackenzie GG, Wang Y.
    Food Funct; 2018 Nov 14; 9(11):5682-5696. PubMed ID: 30310905
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.